Patient characteristics
Characteristics . | Data . |
|---|---|
| No. male/no. female | 33/38 |
| Median age, y (range) | 39 (5-70) |
| Donor type, no. (%) | |
| Matched sibling | 43 (61) |
| Matched, unrelated | 19 (27) |
| Mismatched, related | 5 (7) |
| Mismatched, unrelated | 4 (6) |
| Diagnosis, no. (%) | |
| ALL | 2 (3) |
| AML/MDS | 29 (41) |
| CLL | 1 (1) |
| CML/MPD | 21 (30) |
| Lymphoma | 14 (20) |
| Aplastic anemia | 2 (3) |
| Sickle-cell anemia | 1 (1) |
| Breast cancer | 1 (1) |
| GVHD prophylaxis, no. (%) | |
| Tacrolimus/MTX | 65 (91) |
| Tacrolimus/steroids | 5 (7) |
| Cyclosporine/MTX | 1 (2) |
| Grades 2-4 acute GVHD, no. (%) | 39 (55) |
| Type of chronic GVHD, no. (%) | |
| De novo | 18 (25.5) |
| Progressive | 18 (25.5) |
| Relapsing | 35 (49) |
| Extensive chronic GVHD, no. (%) | 52 (73) |
| Corticosteroids at the time of ECP, no. (%) | 59 (83) |
Characteristics . | Data . |
|---|---|
| No. male/no. female | 33/38 |
| Median age, y (range) | 39 (5-70) |
| Donor type, no. (%) | |
| Matched sibling | 43 (61) |
| Matched, unrelated | 19 (27) |
| Mismatched, related | 5 (7) |
| Mismatched, unrelated | 4 (6) |
| Diagnosis, no. (%) | |
| ALL | 2 (3) |
| AML/MDS | 29 (41) |
| CLL | 1 (1) |
| CML/MPD | 21 (30) |
| Lymphoma | 14 (20) |
| Aplastic anemia | 2 (3) |
| Sickle-cell anemia | 1 (1) |
| Breast cancer | 1 (1) |
| GVHD prophylaxis, no. (%) | |
| Tacrolimus/MTX | 65 (91) |
| Tacrolimus/steroids | 5 (7) |
| Cyclosporine/MTX | 1 (2) |
| Grades 2-4 acute GVHD, no. (%) | 39 (55) |
| Type of chronic GVHD, no. (%) | |
| De novo | 18 (25.5) |
| Progressive | 18 (25.5) |
| Relapsing | 35 (49) |
| Extensive chronic GVHD, no. (%) | 52 (73) |
| Corticosteroids at the time of ECP, no. (%) | 59 (83) |
ALL indicates acute lymphoblastic leukemia; AML/MDS, acute myelogenous leukemia/myelodysplastic syndrome; CML/MPD, chronic myelogenous leukemia/myeloproliferative disorders; ECP, extracorporeal photopheresis; and MTX, methotrexate.